$0.1850
-0.0142-7.13%
IGC Pharma (IGC) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
| Metric | Q2 '27 | Q1 '27 | Q3 '26 | Q2 '26 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.02 | — | $-0.02 | $-0.02 |
| Actual | $-0.03 | $-0.02 | $-0.01 | $-0.02 |
| Surprise | -50.0% | — | +50.0% | 0.00% |
| Revenue | ||||
| Estimate | $160000 | — | $392100 | $353800 |
| Actual | $265000 | $317000 | $213000 | $191000 |
| Surprise | +65.6% | — | -45.7% | -46.0% |
| Metric | Q3 '27E | Q4 '27E | Q1 '28E |
|---|---|---|---|
| Earnings Per Share (Non-GAAP) | |||
| Consensus | $-0.02 | $-0.02 | $-0.02 |
| Revenue | |||
| Consensus | $100000 | $280000 | — |
| Trimestre fiscale | Data segnalata | EPS effettivo | EPS stimato | Sorpresa% |
|---|---|---|---|---|
| Q2 | Aug 17, 2026 | $-0.03 | $-0.02 | -50.0 % |
| Q3 | Mar 19, 2026 | $-0.01 | $-0.02 | 50.0 % |
| Q2 | Nov 17, 2025 | $-0.02 | $-0.02 | 0.00 % |
| Q1 | Aug 14, 2025 | $-0.02 | $-0.03 | 33.3 % |
| Trimestre fiscale | Data segnalata | Entrate effettive | Entrate stimate | Sorpresa% |
|---|---|---|---|---|
| Q2 | Aug 17, 2026 | $265.00K | $160.00K | 65.6 % |
| Q3 | Mar 19, 2026 | $213.00K | $392.10K | -45.7 % |
| Q2 | Nov 17, 2025 | $191.00K | $353.80K | -46.0 % |
| Q1 | Aug 14, 2025 | $328.00K | $327.60K | 0.12 % |